Nerviano Medical Sciences Srl:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nerviano Medical Sciences Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7551
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nerviano Medical Sciences Srl (NMS) is a drug development company that discovers and develops novel anticancer drugs. The company’s pipeline products include anticancer compounds such as Danusertib, Encorafenib, Entrectinib, ADC Payload programs, PARP1 program, NMS-088, Brostallicin, Milciclib, S81694, PCM-075, NMS-P293, and others. It offers clinical and preclinical research, clinical trials, preclinical and clinical development, study management, pharmacovigilance, clinical data management, pharmacological development, biostatistics, programming, medical and scientific writing, and other services. NMS also develops Kinase platform that delivers potent and selective kinase inhibitors in clinical development. The company partners with biopharmaceutical and biotechnology companies for the development of anticancer drugs. NMS is headquartered in Milan, Italy.

Nerviano Medical Sciences Srl – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
European Institute of Oncology Enters Into Agreement With Nerviano Medical Sciences For Anti-Cancer Drugs 10
Licensing Agreements 11
Merck Enters into Licensing Agreement with Nerviano Medical Sciences 11
Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 12
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 13
Tiziana Life Sciences Enters into Licensing Agreement with Nerviano Medical Sciences for Milciclib 14
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 15
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 18
MediaPharma Enters into Licensing Agreement with Nerviano Medical Sciences 20
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 21
Acquisition 23
Shanghai Advanced Research to Acquire 90% Stake in Nerviano Medical for USD355.9 Million 23
Nerviano Medical Sciences Srl – Key Competitors 24
Nerviano Medical Sciences Srl – Key Employees 25
Nerviano Medical Sciences Srl – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Key Facts 2
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nerviano Medical Sciences Srl, Deals By Therapy Area, 2012 to YTD 2018 8
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
European Institute of Oncology Enters Into Agreement With Nerviano Medical Sciences For Anti-Cancer Drugs 10
Merck Enters into Licensing Agreement with Nerviano Medical Sciences 11
Trovagene Enters into Licensing Agreement with Nerviano Medical Sciences for PCM-075 12
Oxford BioTherapeutics Enters into Licensing Agreement with Nerviano Medical Sciences 13
Tiziana Life Sciences Enters into Licensing Agreement with Nerviano Medical Sciences for Milciclib 14
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for RXDX-103 and RXDX-104 Inhibitors 15
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences 17
Ignyta Amends Licensing Agreement with Nerviano Medical Sciences for Tyrosine Kinase Inhibitors 18
MediaPharma Enters into Licensing Agreement with Nerviano Medical Sciences 20
Nerviano Medical Sciences And Servier Enter Into Licensing Agreement For Anticancer Drug 21
Shanghai Advanced Research to Acquire 90% Stake in Nerviano Medical for USD355.9 Million 23
Nerviano Medical Sciences Srl, Key Competitors 24
Nerviano Medical Sciences Srl, Key Employees 25
Nerviano Medical Sciences Srl, Subsidiaries 26

List of Figures
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nerviano Medical Sciences Srl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Nerviano Medical Sciences Srl:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Centre for Drug Design and Discovery-製薬・医療分野:企業M&A・提携分析
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution provides services such as silico molecule design, modelling and screening, medicinal chemistry, intellectual property rights support, business development, …
  • Beach Energy Ltd (BPT):企業の財務・戦略的SWOT分析
    Beach Energy Ltd (BPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bio2 Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Bio2 Medical Inc (Bio2 Medical) is a medical device company that develops vascular devices. The company’s products include angel catheter, an inferior vena cava filter for pulmonary embolism protection and access to the central venous system in critically ill patients. Its device is designed …
  • Luxair S.A.:企業の戦略・SWOT・財務情報
    Luxair S.A. - Strategy, SWOT and Corporate Finance Report Summary Luxair S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Pathfinder Energy Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pathfinder Energy Pty Ltd (Pathfinder) is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas resources. The company acquires exploration permits and matures prospects using geophysics and geology. It maintains exploration licenses in …
  • Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析
    Summary Luye Pharma Group Ltd (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd is a drug development company that discovers, manufactures, and commercializes novel formulations, generic drugs, and pharmaceutical products. The company offers its products in the form of tablets, formulation …
  • PledPharma AB (PLED):製薬・医療:M&Aディール及び事業提携情報
    Summary PledPharma AB (PledPharma) is a pharmaceutical company that discovers, manufactures, and develops drugs that protect the body against oxidative stress. The company discovers and develops Aladote and PledOx drugs. Its PledOX drug is used to prevent chemotherapy-induced side effects for colore …
  • Eni SpA (ENI):企業の財務・戦略的SWOT分析
    Eni SpA (ENI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Ergon Inc:企業の戦略・SWOT・財務情報
    Ergon Inc - Strategy, SWOT and Corporate Finance Report Summary Ergon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Phatra Leasing Public Company Limited (PL):企業の財務・戦略的SWOT分析
    Phatra Leasing Public Company Limited (PL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Gentag Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gentag Inc (Gentag) is a medical device company that patent and develops wireless sensor technology products. The company provides wireless products to diagnostics and personal health. It offers wireless sensor network services. Gentag’s products comprise medication and packaging sensor, dia …
  • Corgenix Medical Corp:医療機器:M&Aディール及び事業提携情報
    Summary Corgenix Medical Corp (Corgenix), a subsidiary of Orgentec Diagnostika GmbH is a medical device company that offers medical diagnostic solutions. The company offers vascular disease products, infectious disease products, non-invasive liver biomarkers, and instrumentation. It offers an instru …
  • Delegat’s Group Limited:企業の戦略・SWOT・財務分析
    Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report Summary Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Medivir AB (MVIR B):企業の財務・戦略的SWOT分析
    Summary Medivir AB (Medivir) is a pharmaceutical company. It is engaged in drug discovery and development of treatments for cancer.The company offers products under development for the treatment of cutaneous T-cell lymphoma, osteoarthritis, solid tumors, hepatocellular carcinoma and acute myeloid le …
  • Thai Rubber Latex Corp (Thailand) Public Co Ltd (TRUBB):企業の財務・戦略的SWOT分析
    Thai Rubber Latex Corp (Thailand) Public Co Ltd (TRUBB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’ …
  • MITIE Group Plc (MTO):企業の財務・戦略的SWOT分析
    MITIE Group Plc (MTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Leukocare AG-製薬・医療分野:企業M&A・提携分析
    Summary Leukocare AG (Leukocare) is a clinical stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company offers services such as development of individual SPS formulations meeting i …
  • Shoppers Drug Mart Corporation:企業の戦略・SWOT・財務情報
    Shoppers Drug Mart Corporation - Strategy, SWOT and Corporate Finance Report Summary Shoppers Drug Mart Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Handok Inc (002390)-医療機器分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Nationwide Financial Services, Inc.:企業の戦略的SWOT分析
    Nationwide Financial Services, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆